FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3003143162> ?p ?o ?g. }

• W3003143162 abstract "Despite the unprecedented success of immune checkpoint blockade (ICB) in melanoma and other cancers, tackling innate (primary) resistance remains a major challenge and robust biomarkers to guide treatment are lacking. Clinical trials are already underway evaluating novel immune modulatory agents in combination with anti-PD-1/PD-L1 therapies in an effort to overcome innate resistance. Despite increasing reports of ‘rational’ combination strategies, these therapies remain “one size fits all”, due the lack of robust biomarkers to guide clinical decision-making. There is an unmet need for novel approaches, tools, techniques, and methods for pre-clinical and clinical use to better understand mechanisms of response and resistance to immune checkpoint inhibitors and next-generation anti-tumor immune modulatory drugs. We have adapted a 3D microfluidic device to the short-term culture of murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS)for functional ex vivo profiling of PD-1 blockade in a model tumor immune microenvironment (TIME) to facilitate identification of mediators of response and resistance to ICB and to guide development of next-generation immunotherapy combinations. The MDOTS/PDOTS platform provides a window into the complex and dynamic events of the TIME during response (and resistance) to ICB and is an ideal model system for pre-clinical evaluation of novel cancer immunotherapy targets. Focused evaluation of novel treatment combinations using MDOTS identified TANK-binding kinase 1 (TBK1) as a novel cancer immunotherapy target, mirroring in vivoefficacy of this treatment approach. TBK1 is a Ser/Thr kinase involved in innate immune signaling and is an emerging target for anti-cancer therapy. Importantly, independent orthogonal data from two different laboratories has also identified TBK1 as a cancer immunotherapy target.We have confirmed that Tbk1 deletion and/or TBK1 pharmacologic inhibition enhances response to in vivo anti-PD-1 therapy, and have characterized the impact of deletion of Tbk1 (CRISPR) or pharmacologic inhibition of TBK1 (Cmpd1) on the tumor-immune microenvironment.Lastly, we confirmed that resistance to PD-1 blockade can be overcome with pharmacologic TBK1 inhibition using murine- and patient-derived organotypic tumor spheroids in 3D microfluidic culture. These findings confirm TBK1 as a target to overcome resistance to PD-1 blockade, further supporting the pre-clinical and clinical development of this novel combination strategy. REFERENCES 1. Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118(1):9-16. doi: 10.1038/bjc.2017.434. PubMed PMID: 29319049; PMCID: PMC5765236. 2. Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, Miller BC, Collins NB, Bi K, LaFleur MW, Juneja VR, Weiss SA, Lo J, Fisher DE, Miao D, Van Allen E, Root DE, Sharpe AH, Doench JG, Haining WN. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017. doi: 10.1038/nature23270. PubMed PMID: 28723893. 3. Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay RE, Luoma AM, Tsoucas D, Qiu X, Lim K, Rao P, Long HW, Yuan GC, Doench J, Brown M, Liu XS, Wucherpfennig KW. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018;359(6377):770-5. doi: 10.1126/science.aao1710. PubMed PMID: 29301958. Citation Format: Ajaykumar Vishwakarma, Yi Sun, Amina Fu, Emily Robitschek, Arvin Iracheta-Vellve, Susanna Stinson, Aliasger Salem, Robert Manguso, Russell Jenkins. TANK-Binding Kinase 1 (TBK1) as a novel cancer immunotherapy target [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B065. doi:10.1158/1535-7163.TARG-19-B065" @default.
• W3003143162 created "2020-01-30" @default.
• W3003143162 creator A5002551319 @default.
• W3003143162 creator A5008556009 @default.
• W3003143162 creator A5024224423 @default.
• W3003143162 creator A5030438113 @default.
• W3003143162 creator A5033056679 @default.
• W3003143162 creator A5034793554 @default.
• W3003143162 creator A5041947795 @default.
• W3003143162 creator A5079433380 @default.
• W3003143162 creator A5082908624 @default.
• W3003143162 date "2019-12-01" @default.
• W3003143162 modified "2023-09-27" @default.
• W3003143162 title "Abstract B065: TANK-Binding Kinase 1 (TBK1) as a novel cancer immunotherapy target" @default.
• W3003143162 doi "https://doi.org/10.1158/1535-7163.targ-19-b065" @default.
• W3003143162 hasPublicationYear "2019" @default.
• W3003143162 type Work @default.
• W3003143162 sameAs 3003143162 @default.
• W3003143162 citedByCount "0" @default.
• W3003143162 crossrefType "proceedings-article" @default.
• W3003143162 hasAuthorship W3003143162A5002551319 @default.
• W3003143162 hasAuthorship W3003143162A5008556009 @default.
• W3003143162 hasAuthorship W3003143162A5024224423 @default.
• W3003143162 hasAuthorship W3003143162A5030438113 @default.
• W3003143162 hasAuthorship W3003143162A5033056679 @default.
• W3003143162 hasAuthorship W3003143162A5034793554 @default.
• W3003143162 hasAuthorship W3003143162A5041947795 @default.
• W3003143162 hasAuthorship W3003143162A5079433380 @default.
• W3003143162 hasAuthorship W3003143162A5082908624 @default.
• W3003143162 hasConcept C121608353 @default.
• W3003143162 hasConcept C126322002 @default.
• W3003143162 hasConcept C170493617 @default.
• W3003143162 hasConcept C203014093 @default.
• W3003143162 hasConcept C2776107976 @default.
• W3003143162 hasConcept C2777701055 @default.
• W3003143162 hasConcept C2778468042 @default.
• W3003143162 hasConcept C2780030458 @default.
• W3003143162 hasConcept C2780674031 @default.
• W3003143162 hasConcept C2780851360 @default.
• W3003143162 hasConcept C502942594 @default.
• W3003143162 hasConcept C535046627 @default.
• W3003143162 hasConcept C71924100 @default.
• W3003143162 hasConcept C8891405 @default.
• W3003143162 hasConceptScore W3003143162C121608353 @default.
• W3003143162 hasConceptScore W3003143162C126322002 @default.
• W3003143162 hasConceptScore W3003143162C170493617 @default.
• W3003143162 hasConceptScore W3003143162C203014093 @default.
• W3003143162 hasConceptScore W3003143162C2776107976 @default.
• W3003143162 hasConceptScore W3003143162C2777701055 @default.
• W3003143162 hasConceptScore W3003143162C2778468042 @default.
• W3003143162 hasConceptScore W3003143162C2780030458 @default.
• W3003143162 hasConceptScore W3003143162C2780674031 @default.
• W3003143162 hasConceptScore W3003143162C2780851360 @default.
• W3003143162 hasConceptScore W3003143162C502942594 @default.
• W3003143162 hasConceptScore W3003143162C535046627 @default.
• W3003143162 hasConceptScore W3003143162C71924100 @default.
• W3003143162 hasConceptScore W3003143162C8891405 @default.
• W3003143162 hasLocation W30031431621 @default.
• W3003143162 hasOpenAccess W3003143162 @default.
• W3003143162 hasPrimaryLocation W30031431621 @default.
• W3003143162 hasRelatedWork W12166029 @default.
• W3003143162 hasRelatedWork W17404775 @default.
• W3003143162 hasRelatedWork W20510985 @default.
• W3003143162 hasRelatedWork W2151330 @default.
• W3003143162 hasRelatedWork W2773312 @default.
• W3003143162 hasRelatedWork W5924046 @default.
• W3003143162 hasRelatedWork W6417289 @default.
• W3003143162 hasRelatedWork W7733468 @default.
• W3003143162 hasRelatedWork W9749177 @default.
• W3003143162 hasRelatedWork W15255855 @default.
• W3003143162 isParatext "false" @default.
• W3003143162 isRetracted "false" @default.
• W3003143162 magId "3003143162" @default.
• W3003143162 workType "article" @default.